Down-regulation of C-type natriuretic peptide receptor by vasonatrin peptide in cardiac myocytes and fibroblasts

Acta Pharmacologica Sinica

Volumn 25, Issue 4, 2004, Pages 424-430

  Lü, Shun Yan ^a   Zhu, Miao Zhang ^a   Wang, Dian Shi ^a   Yu, Jun ^a   Guo, Hai Tao ^a   Hu, Yu Zhen ^a   Wei, Qi Ming ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

C type natriuretic peptide; Fibroblasts; Hypoxia; Myocardium

Indexed keywords

8 BROMO CYCLIC GMP; CYCLIC GMP; GUANYLATE CYCLASE INHIBITOR; HS 142 1; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; PEPTIDE; RECEPTOR; UNCLASSIFIED DRUG; VASONATRIN;

AIR; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; FIBROBLAST; HEART CELL CULTURE; HYPOXIA; MEMBRANE PERMEABILITY; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; ATRIAL NATRIURETIC FACTOR; CELL HYPOXIA; CELLS, CULTURED; CYCLIC GMP; DOWN-REGULATION; FIBROBLASTS; GUANYLATE CYCLASE; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RNA, MESSENGER;

EID: 1842708972     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Foster DC, Garber DL, Wedel BJ. The guanylyl cyclase-A receptor. In: Samson WK, Levin ER, editors. Contemporary endocrinology: natriuretic peptides in health and disease. Totowa, NJ: Humana; 1997. p 21-34.
2. Lewicki JA, Protter AA. Molecular determinations of natriuretic peptide clearance receptor function. In: Samson WK, Levin ER, editors. Contemporary endocrinology: natriuretic peptides in health and disease. Totowa, NJ: Humana; 1997. p 51-70.
3. Schulz S, Singh S, Bellet RA, Singh G, Tubb DJ, Chin H, et al. The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell 1989; 58: 1155-62.
4. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbit; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 1999; 289: 976-80.
5. Sun JZ, Chen SJ, Li GH, Chen YF. Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am J Physiol Lung Cell Mol Physiol 2000; 279: L511-19.
6. Li H, Oparil S, Meng QC, Elton TS, Chen YF. Selective down-regulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. Am J Physiol 1995; 268 (2 Pt 1): L328-35.
7. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail 2001; 3: 407-14.
8. Kim SZ, Cho KW, Kim SH. Modulation of endocardial natriuretic peptide receptor in right ventricular hypertrophy. Am J Physiol 1999; 277: H2280-9.
9. Klinger JR, Arnal R, Warburton RR, Ou LC, Hill NS. Downregulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia. J Appl Physiol 1994; 77: 1309-16.
10. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-34.
11. Lin X, Hanze J, Heese F, Sodmann R, Lang RE. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 1995; 77: 750-8.
12. Perrella MA, Aarhus LL, Heublein DM, Lewicki JA, Burnett JC Jr. Biological role of atrial natriuretic factor clearance receptor in congestive heart failure. Am J Physiol 1993; 265: H401-8.
13. Brown LA, Rutherford RA, Nunez DJ, Wharton J, Lowe DG, Wilkins MR. Downregulation of natriuretic peptide C-receptor protein in the hypertrophied ventricle of the aortovenocaval fistula rat. Cardiovasc Res 1997; 36: 363-71.
14. Wei CM, Kim CH, Miller VM, Burnett JC Jr. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993; 92: 2048-52.
15. Feng HS, Zang YM, Zhu MZ, Wang YM, Wang L, Shi PT. Comparison of inhibitory effects of vasonatrin peptide, c-type natriuretic peptides and atrial natriuretic peptide on pulmonary artery hypertension induced by chronic hypoxia in rat. Chin J Tuberc Respir Dis 2000; 23: 427-8.
16. Guo HT, Zhu MZ, Lü SY, Yu J, Dong MQ, Gao Z, et al. Vasonatrin peptide attenuates hypoxia-induced increase in calcium of cultured rat cardiac fibroblasts. Acta Physiol Sin 2001; 53: 286-90.
17. Yu J, Dong MQ, Lü SY, Zhu MZ. Use of vasonatrin peptide in the attenuation of norepinephrine-induced growth-promoting effects on cardiac myocytes. Chin J Cardiac Fun 1999; 11: 145-8.
18. Matsubara H, Hirata Y, Yoshimi H, Takata S, Takagi Y, Umeda Y, et al. Role of calcium and protein kinase C in ANP secretion by cultured rat cardiocytes. Am J Physiol 1988; 255: H405-9.
19. Dostal DE, Rothblum KN, Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol 1992; 263: C851-63.
20. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994; 75: 426-33.
21. Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B, Bishopric NH. Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 1999; 104: 239-52.
22. Wang HX, Ma XC, Deng QL, Li D. Cytotoxicity of flutamide and 2-hydroxyglutamide and their effects on CYP1A2 mRNA in primary rat hepatocytes. Acta Pharmacol Sin 2002; 23: 562-6.
23. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995; 4: 357-62.
24. Morishita Y, Sano T, Ando K, Saitoch Y, Kase H, Yamada K, et al. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun 1991; 176: 949-57.
25. Schenk DB, Phelps MN, Porter JG, Scarborough RM, McEnroe GA, Lewicki JA. Identification of the receptor for atrial natriuretic factor on cultured vascular cells. J Biol Chem 1985; 260: 14887-90.
26. Martin ER, Lewicki JA, Scarborough M, Ballerman BJ. Expression and regulation of ANP receptor subtypes in rat renal glomeruli and papillae. Am J Phyiol 1989; 257: F649-57.
27. Hystad ME, Oie E, Grogaard HK, Kuusnemi K, Vuolteenaho O, Attramadal H, et al. Gene expression of natriuretic peptides and their receptors type-A and -C after myocardial infarction in rat. Scand J Clin Lab Invest 2001; 61: 139-50.
28. Lü SY, Zhu MZ, Guo HT, Yu J, Wei CM. Inhibition of moderate hypoxia-induced protein synthesis by vasonatrin peptide in cultured neonatal rat cardiomyocytes. Acta Physiol Sin 2002; 54: 7-11.